Japan grants $1.3bn in new subsidies to bolster domestic flu vaccine capacity
This article was originally published in Scrip
Having learnt a lesson from past problems, Japan is looking to build up its national manufacturing capacity for H1N1 influenza vaccines through a new round of government grants to several major domestic producers, including Takeda and Daiichi Sankyo.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.